These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

576 related articles for article (PubMed ID: 28216195)

  • 1. Golimumab in real-life settings: 2 Years drug survival and predictors of clinical outcomes in rheumatoid arthritis, spondyloarthritis, and psoriatic arthritis.
    Iannone F; Santo L; Anelli MG; Bucci R; Semeraro A; Quarta L; D'Onofrio F; Marsico A; Carlino G; Casilli O; Cacciapaglia F; Zuccaro C; Falappone PC; Cantatore FP; Muratore M; Lapadula G
    Semin Arthritis Rheum; 2017 Aug; 47(1):108-114. PubMed ID: 28216195
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Four-year follow-up of inflammatory arthropathy patients treated with golimumab: Data from the observational multicentre NOR-DMARD study.
    Michelsen B; Sexton J; Wierød A; Bakland G; Rødevand E; Krøll F; Kvien TK
    Semin Arthritis Rheum; 2020 Feb; 50(1):12-16. PubMed ID: 31358361
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influence of baseline modified Rheumatic Disease Comorbidity Index (mRDCI) on drug survival and effectiveness of biological treatment in patients affected with Rheumatoid arthritis, Spondyloarthritis and Psoriatic arthritis in real-world settings.
    Iannone F; Salaffi F; Fornaro M; Di Carlo M; Gentileschi S; Cantarini L; Lopalco G
    Eur J Clin Invest; 2018 Nov; 48(11):e13013. PubMed ID: 30079593
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Golimumab effectiveness in biologic inadequate responding patients with rheumatoid arthritis, psoriatic arthritis and spondyloarthritis in real-life from the Italian registry GISEA.
    Iannone F; Favalli EG; Caporali R; D'Angelo S; Cantatore FP; Sarzi-Puttini P; Foti R; Conti F; Carletto A; Gremese E; Cauli A; Ramonda R; Palermo A; Epis O; Priora M; Bergossi F; Frediani B; Salaffi F; Lopalco G; Cacciapaglia F; Marchesoni A; Biggioggiero M; Bugatti S; Balduzzi S; Carriero A; Corrado A; Bongiovanni S; Benenati A; Miranda F; Fracassi E; Perra D; Ferraccioli G; Lapadula G
    Joint Bone Spine; 2021 Jan; 88(1):105062. PubMed ID: 32755721
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effectiveness of Certolizumab-Pegol in Rheumatoid Arthritis, Spondyloarthritis, and Psoriatic Arthritis Based on the BIOPURE Registry: Can Early Response Predict Late Outcomes?
    Iannone F; Semeraro A; Carlino G; Santo L; Bucci R; Quarta L; Maruotti N; Zuccaro C; Marsico A; Falappone PCF; Mazzotta D; Cantatore FP; Muratore M; Lapadula G
    Clin Drug Investig; 2019 Jun; 39(6):565-575. PubMed ID: 30941736
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The persistence of golimumab compared to other tumour necrosis factor-α inhibitors in daily clinical practice for the treatment of rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis: observations from the Slovenian nation-wide longitudinal registry of patients treated with biologic disease-modifying antirheumatic drugs-BioRx.si.
    Rotar Ž; Tomšič M; Praprotnik S;
    Clin Rheumatol; 2019 Feb; 38(2):297-305. PubMed ID: 30324406
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term retention of golimumab treatment in clinical practice in a large cohort of patients with rheumatoid arthritis, axial spondyloarthritis and psoriatic arthritis.
    Pombo-Suárez M; Seoane-Mato D; Díaz-González F; Cea-Calvo L; Sánchez-Alonso F; Sánchez-Jareño M; Jovani V; García-Magallón B; Martínez-González O; Campos-Fernández C; Manero J; Díaz-Torne C; Bohórquez C; Ros-Vilamajó I; Pérez-Vera Y; Castrejón I
    Musculoskeletal Care; 2023 Mar; 21(1):189-197. PubMed ID: 35996810
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Factors associated with long-term retention of treatment with golimumab in rheumatoid arthritis, axial spondyloarthritis, and psoriatic arthritis: an analysis of the Spanish BIOBADASER registry.
    Pombo-Suarez M; Sanchez-Piedra C; Garcia-Magallón B; Pérez-Gómez A; Manrique-Arija S; Martín-Doménech R; Colazo M; Campos C; Campos J; Del Pino-Montes J; Arteaga MJ; Cea-Calvo L; Díaz-González F; Gómez-Reino JJ
    Clin Rheumatol; 2021 Oct; 40(10):3979-3988. PubMed ID: 33907904
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High 3-year golimumab survival in patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis: real world data from 328 patients.
    Thomas K; Flouri I; Repa A; Fragiadaki K; Sfikakis PP; Koutsianas C; Kaltsonoudis E; Voulgari PV; Drosos AA; Petrikkou E; Sidiropoulos P; Vassilopoulos D
    Clin Exp Rheumatol; 2018; 36(2):254-262. PubMed ID: 29148406
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Two-year retention rate of golimumab in rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis: data from the LORHEN registry.
    Manara M; Caporali R; Favalli EG; Grosso V; Atzeni F; Sarzi Puttini P; Gorla R; Bazzani C; Fusaro E; Pellerito R; Rocchetta PA; Sinigaglia L
    Clin Exp Rheumatol; 2017; 35(5):804-809. PubMed ID: 28770712
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-Term Retention Rate of Golimumab in Patients With Rheumatoid Arthritis, Psoriatic Arthritis, and Spondyloarthritis in a Real-Life Setting.
    Serrano-Benavente B; Valor L; Del Río Blasco T; Janta I; González Benítez R; Nieto-González JC; Martínez-Barrio J; Ovalles Bonilla JG; Ariza A; López-Longo FJ; Álvaro-Gracia JM; Monteagudo I; González-Fernández CM
    J Clin Rheumatol; 2022 Jan; 28(1):e150-e155. PubMed ID: 33492028
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Early identification of golimumab-treated patients with higher likelihood of long-term retention.
    García-Dorta A; González-Dávila E; Sánchez-Jareño M; Cea-Calvo L; Pombo-Suárez M; Sánchez-Alonso F; Castrejón I; Díaz-González F
    Front Immunol; 2024; 15():1359571. PubMed ID: 38680482
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Factors associated with long-term retention of treatment with golimumab in a real-world setting: an analysis of the Spanish BIOBADASER registry.
    Hernandez MV; Sanchez-Piedra C; Garcia-Magallon B; Cuende E; Manero J; Campos-Fernandez C; Martin-Domenech R; Del Pino-Montes J; Manrique S; Castro-Villegas MC; Ruiz-Montesinos D; Sanchez-Alonso F; Diaz-Gonzalez F; Cea-Calvo L; Gómez-Reino JJ;
    Rheumatol Int; 2019 Mar; 39(3):509-515. PubMed ID: 30353269
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Two-year survival rates of anti-TNF-α therapy in psoriatic arthritis (PsA) patients with either polyarticular or oligoarticular PsA.
    Iannone F; Lopriore S; Bucci R; Scioscia C; Anelli MG; Notarnicola A; Lapadula G
    Scand J Rheumatol; 2015 May; 44(3):192-9. PubMed ID: 25564882
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative Analysis and Predictors of 10-year Tumor Necrosis Factor Inhibitors Drug Survival in Patients with Spondyloarthritis: First-year Response Predicts Longterm Drug Persistence.
    Flouri ID; Markatseli TE; Boki KA; Papadopoulos I; Skopouli FN; Voulgari PV; Settas L; Zisopoulos D; Iliopoulos A; Geborek P; Drosos AA; Boumpas DT; Sidiropoulos P
    J Rheumatol; 2018 Jun; 45(6):785-794. PubMed ID: 29606666
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Two-year persistence of golimumab as second-line biologic agent in rheumatoid arthritis as compared to other subcutaneous tumor necrosis factor inhibitors: real-life data from the LORHEN registry.
    Favalli EG; Sinigaglia L; Becciolini A; Grosso V; Gorla R; Bazzani C; Atzeni F; Sarzi Puttini PC; Fusaro E; Pellerito R; Caporali R
    Int J Rheum Dis; 2018 Feb; 21(2):422-430. PubMed ID: 29082659
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness and safety of golimumab in patients with rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis under real-life clinical conditions: non-interventional GO-NICE study in Germany.
    Krüger K; Burmester GR; Wassenberg S; Bohl-Bühler M; Thomas MH
    BMJ Open; 2018 Jun; 8(6):e021082. PubMed ID: 29903793
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drug survival of the first course of anti-TNF agents in patients with rheumatoid arthritis and seronegative spondyloarthritis: analysis from the MonitorNet database.
    Scirè CA; Caporali R; Sarzi-Puttini P; Frediani B; Di Franco M; Tincani A; Sinigaglia L; Sfriso P; Tirri R; Bellis E; Delsante G; Porru G; Salaffi F; Giuggioli D; Rossini M; Todoerti M; Bazzichi L; Govoni M; Gerli R; Raschetti R; Minisola G; Montecucco C; Todesco S;
    Clin Exp Rheumatol; 2013; 31(6):857-63. PubMed ID: 23981363
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Persistence of biological agents over an eight-year period in rheumatoid arthritis and spondyloarthritis patients.
    González-Fernández MÁ; Villamañán E; Jiménez-Nácher I; Moreno F; Herrero A; Balsa A
    Farm Hosp; 2019 Jan; 43(1):24-30. PubMed ID: 30624170
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Eight-Year Retention Rate of First-Line Tumor Necrosis Factor Inhibitors in Spondyloarthritis: A Multicenter Retrospective Analysis.
    Favalli EG; Selmi C; Becciolini A; Biggioggero M; Ariani A; Santilli D; Fusaro E; Parisi S; Massarotti M; Marchesoni A; Meroni PL
    Arthritis Care Res (Hoboken); 2017 Jun; 69(6):867-874. PubMed ID: 27696735
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.